vs

Side-by-side financial comparison of CareDx, Inc. (CDNA) and PROVIDENT FINANCIAL SERVICES INC (PFS). Click either name above to swap in a different company.

PROVIDENT FINANCIAL SERVICES INC is the larger business by last-quarter revenue ($225.2M vs $117.7M, roughly 1.9× CareDx, Inc.). PROVIDENT FINANCIAL SERVICES INC runs the higher net margin — 35.3% vs 2.4%, a 32.9% gap on every dollar of revenue. Over the past eight quarters, PROVIDENT FINANCIAL SERVICES INC's revenue compounded faster (17.3% CAGR vs 12.9%).

CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.

The PNC Financial Services Group, Inc. is an American bank holding company and financial services corporation based in Pittsburgh, Pennsylvania. Its banking subsidiary, PNC Bank, operates in 27 states and the District of Columbia, with 2,629 branches and 9,523 ATMs. PNC Bank is one of the largest banks in the US by assets and by number of branches, deposits, and ATMs.

CDNA vs PFS — Head-to-Head

Bigger by revenue
PFS
PFS
1.9× larger
PFS
$225.2M
$117.7M
CDNA
Higher net margin
PFS
PFS
32.9% more per $
PFS
35.3%
2.4%
CDNA
Faster 2-yr revenue CAGR
PFS
PFS
Annualised
PFS
17.3%
12.9%
CDNA

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CDNA
CDNA
PFS
PFS
Revenue
$117.7M
$225.2M
Net Profit
$2.8M
$79.4M
Gross Margin
Operating Margin
1.0%
Net Margin
2.4%
35.3%
Revenue YoY
39.0%
Net Profit YoY
24.0%
EPS (diluted)
$0.05
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDNA
CDNA
PFS
PFS
Q1 26
$117.7M
$225.2M
Q4 25
$108.4M
$225.7M
Q3 25
$100.1M
$221.8M
Q2 25
$86.7M
$214.2M
Q1 25
$84.7M
$208.8M
Q4 24
$86.6M
$205.9M
Q3 24
$82.9M
$210.6M
Q2 24
$92.3M
$163.8M
Net Profit
CDNA
CDNA
PFS
PFS
Q1 26
$2.8M
$79.4M
Q4 25
$-4.1M
Q3 25
$1.7M
$71.7M
Q2 25
$-8.6M
$72.0M
Q1 25
$-10.4M
$64.0M
Q4 24
$87.7M
Q3 24
$-10.6M
$46.4M
Q2 24
$-4.6M
$-11.5M
Operating Margin
CDNA
CDNA
PFS
PFS
Q1 26
1.0%
Q4 25
-5.6%
49.7%
Q3 25
-0.2%
45.8%
Q2 25
-12.8%
47.8%
Q1 25
-15.8%
44.0%
Q4 24
97.5%
30.5%
Q3 24
-16.6%
31.0%
Q2 24
-7.9%
-13.0%
Net Margin
CDNA
CDNA
PFS
PFS
Q1 26
2.4%
35.3%
Q4 25
-3.8%
Q3 25
1.7%
32.3%
Q2 25
-9.9%
33.6%
Q1 25
-12.2%
30.7%
Q4 24
101.3%
Q3 24
-12.8%
22.0%
Q2 24
-5.0%
-7.0%
EPS (diluted)
CDNA
CDNA
PFS
PFS
Q1 26
$0.05
$0.61
Q4 25
$-0.08
$0.64
Q3 25
$0.03
$0.55
Q2 25
$-0.16
$0.55
Q1 25
$-0.19
$0.49
Q4 24
$1.60
$0.37
Q3 24
$-0.20
$0.36
Q2 24
$-0.09
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDNA
CDNA
PFS
PFS
Cash + ST InvestmentsLiquidity on hand
$77.9M
$222.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.9B
Total Assets
$411.1M
$25.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDNA
CDNA
PFS
PFS
Q1 26
$77.9M
$222.1M
Q4 25
$177.2M
$209.1M
Q3 25
$194.2M
$299.2M
Q2 25
$186.3M
$258.0M
Q1 25
$230.9M
$234.1M
Q4 24
$260.7M
$205.9M
Q3 24
$240.9M
$244.0M
Q2 24
$228.9M
$290.5M
Total Debt
CDNA
CDNA
PFS
PFS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$0
Stockholders' Equity
CDNA
CDNA
PFS
PFS
Q1 26
$2.9B
Q4 25
$303.1M
$2.8B
Q3 25
$311.1M
$2.8B
Q2 25
$327.4M
$2.7B
Q1 25
$379.3M
$2.7B
Q4 24
$378.4M
$2.6B
Q3 24
$273.2M
$2.6B
Q2 24
$264.7M
$2.6B
Total Assets
CDNA
CDNA
PFS
PFS
Q1 26
$411.1M
$25.2B
Q4 25
$413.2M
$25.0B
Q3 25
$432.3M
$24.8B
Q2 25
$444.3M
$24.5B
Q1 25
$489.6M
$24.2B
Q4 24
$491.1M
$24.1B
Q3 24
$477.0M
$24.0B
Q2 24
$466.8M
$24.1B
Debt / Equity
CDNA
CDNA
PFS
PFS
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDNA
CDNA
PFS
PFS
Operating Cash FlowLast quarter
$4.3M
Free Cash FlowOCF − Capex
$514.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDNA
CDNA
PFS
PFS
Q1 26
$4.3M
Q4 25
$21.4M
$442.3M
Q3 25
$37.4M
$98.0M
Q2 25
$9.9M
$186.8M
Q1 25
$-26.6M
$88.5M
Q4 24
$21.9M
$426.4M
Q3 24
$12.5M
$69.2M
Q2 24
$18.9M
$76.5M
Free Cash Flow
CDNA
CDNA
PFS
PFS
Q1 26
$514.0K
Q4 25
$430.7M
Q3 25
$96.7M
Q2 25
$182.6M
Q1 25
$87.4M
Q4 24
$425.1M
Q3 24
$67.9M
Q2 24
$75.5M
FCF Margin
CDNA
CDNA
PFS
PFS
Q1 26
0.4%
Q4 25
190.8%
Q3 25
43.6%
Q2 25
85.2%
Q1 25
41.9%
Q4 24
206.4%
Q3 24
32.2%
Q2 24
46.1%
Capex Intensity
CDNA
CDNA
PFS
PFS
Q1 26
Q4 25
5.1%
Q3 25
0.6%
Q2 25
2.0%
Q1 25
0.5%
Q4 24
0.6%
Q3 24
0.6%
Q2 24
0.6%
Cash Conversion
CDNA
CDNA
PFS
PFS
Q1 26
1.54×
Q4 25
Q3 25
22.30×
1.37×
Q2 25
2.59×
Q1 25
1.38×
Q4 24
0.25×
Q3 24
1.49×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CDNA
CDNA

Financial Results Total$85.0M72%
Patient and digital solutions revenue$16.0M14%
Product revenue$10.3M9%
Other$6.4M5%

PFS
PFS

Net Interest Income$193.7M86%
Noninterest Income$31.5M14%

Related Comparisons